Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2026 · 10-Q
Revenue$31.47M$31.47M+3.3% vs Q1 2025 Net Income$6.32M$6.32M+24.8% vs Q1 2025 EPS Diluted$0.07$0.07+16.7% vs Q1 2025 Gross Profit$19,976,000+3.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$1,194,000N/M Margins · derivedGross margin63.5%+0.0 pt vs Q1 2025
Operating margin5.0%−10.6 pt vs Q1 2025
Net margin20.1%+3.5 pt vs Q1 2025
ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end